| scholarly article | Q13442814 |
| P2093 | author name string | Tomoki Todo | |
| P2860 | cites work | Oncolytic virus therapy using genetically engineered herpes simplex viruses | Q81549503 |
| A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function | Q24562045 | ||
| Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors | Q33794302 | ||
| Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial | Q33905053 | ||
| Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas | Q34297434 | ||
| Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins | Q34463480 | ||
| A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. | Q34583808 | ||
| Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors | Q35023693 | ||
| Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors | Q35051285 | ||
| Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene | Q35760833 | ||
| Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model | Q35800497 | ||
| Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene | Q35890099 | ||
| Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. | Q35945465 | ||
| Oncolytic viral therapies - the clinical experience | Q36318202 | ||
| Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant | Q36826076 | ||
| Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy | Q40178543 | ||
| Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide | Q40181756 | ||
| Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. | Q40205328 | ||
| Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. | Q40219504 | ||
| Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors | Q40251055 | ||
| Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models | Q40327891 | ||
| Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma | Q40352982 | ||
| Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan | Q40390381 | ||
| Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. | Q40453751 | ||
| Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. | Q40464370 | ||
| Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. | Q40788613 | ||
| A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes | Q41467257 | ||
| An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy | Q42542383 | ||
| Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. | Q43675300 | ||
| Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture | Q44460699 | ||
| Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control | Q45417150 | ||
| Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy | Q45420583 | ||
| Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. | Q45420889 | ||
| Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system | Q45422016 | ||
| Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect | Q45723104 | ||
| Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors | Q45741730 | ||
| Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. | Q45745957 | ||
| Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus | Q45745964 | ||
| Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies | Q45747594 | ||
| Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma | Q73438584 | ||
| Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer | Q73924199 | ||
| P433 | issue | 3 | |
| P921 | main subject | brain tumor | Q233309 |
| oncolytic virus | Q1560099 | ||
| P304 | page(s) | 208-213 | |
| P577 | publication date | 2008-07-28 | |
| P1433 | published in | Cell Adhesion and Migration | Q15817193 |
| P1476 | title | "Armed" oncolytic herpes simplex viruses for brain tumor therapy | |
| P478 | volume | 2 |
| Q38096940 | Advance in herpes simplex viruses for cancer therapy |
| Q38194135 | Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy |
| Q34486691 | Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1 |
| Q38159802 | Evolution of oncolytic viruses: novel strategies for cancer treatment |
| Q91938470 | Gene Therapy Tools for Brain Diseases |
| Q28086999 | Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors |
| Q34099721 | Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability |
| Q36512525 | Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors |
| Q35699072 | ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN. |
| Q39339386 | Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells |
| Q89682703 | Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy |
| Q60044040 | Oncolytic herpes simplex virus and immunotherapy |
| Q27007519 | Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates |
| Q35943736 | Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12 |
| Q37615161 | Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells). |
Search more.